Aside from the possibility that the predominantly male investment analyst community might be a tad more focused during Naked Brand Group’s (NASDAQ:NAKD) earnings conferences, there’s not much to get excited about when it comes to NAKD stock. Source: Shutterstock Yes, Naked Brand owns what should be a compelling mix of undergarment brands. Unfortunately, it seems
0 Comments
America’s top airlines are considered some of the best employers in the U.S. Perhaps that’s why competition is so fierce for airline jobs. In 2017, Delta Air Lines, Inc. (DAL) received 200,000 applications for about 1,000 flight attendant openings, meaning fewer than 1% of applicants were hired. Mathematically speaking, that means it is five times harder
0 Comments
“What causes the out-performance of the prosaic old-style stocks over the more exciting trailblazers?” Wharton Business School professor Jeremy Siegel sought to answer that question some 15 years ago in his analysis of dividend stocks. “The answer is simple,” Siegel wrote in The Future for Investors: Why the Tried and True Triumph Over the Bold and
0 Comments
Traders just won’t give up on Luckin Coffee (OTCMKTS:LKNCY). The one-time apparent Starbucks (NASDAQ:SBUX) of China, Luckin stock lost more than 90% of its value this year following revelations of fraud. Source: abolukbas / Shutterstock.com Luckin vastly inflated its reported sales. On the basis of these inaccurate numbers, Luckin sold stock to the public at artificially
0 Comments
For years, Under Armour (NYSE:UAA) has been an eyesore in the otherwise burgeoning athletic apparel market, and Under Armour stock has paid the price. Over the past five years — while Nike (NYSE:NKE) stock has risen 100%, Adidas (OTCMKTS:ADDYY) stock has risen 300% and Lululemon (NASDAQ:LULU) stock has risen 600% — Under Amour has lost
0 Comments
Shares of Vertex (VRTX) declined 20% last week after the company announced the discontinuation of VX-814, the company’s candidate for alpha-1 antitrypsin deficiency. The decline seems disproportionate to the perceived value of this program, but it underscores Vertex’s main weakness – its relatively early-stage and unproven pipeline outside of cystic fibrosis (CF). The stock looks
0 Comments
In my last piece discussing Inovio (NASDAQ:INO) stock, I mentioned reasons to remain positive on the biotech company despite a sharp pullback recently. But it looks like Inovio’s chances for mounting a comeback are slowly slipping away. Source: Ascannio / Shutterstock.com The markets have spoken. They want something concrete from the biotech company before they can
0 Comments